<DOC>
	<DOCNO>NCT00360425</DOCNO>
	<brief_summary>This study define effect ferumoxytol electrocardiogram ( ECG ) data well evaluate pharmacokinetics</brief_summary>
	<brief_title>A Study Electrocardiogram Effects Pharmacokinetics Ferumoxytol Healthy Men Women</brief_title>
	<detailed_description>This trial conduct order provide evaluation potential ferumoxytol cause cardiac arrhythmia accordance International Conference Harmonization ( ICH ) E14 guidance . The purpose trial define effect ferumoxytol electrocardiogram ( ECG ) data . Pharmacokinetics also evaluate multiple time point specify . Subject safety monitor throughout study .</detailed_description>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Healthy adult male female , 18 45 year age , inclusive . Female subject childbearing potential must nonpregnant nonlactating negative serum pregnancy test prior enrollment trial . Subjects must give write informed consent sign Health Insurance Portability Accountability Act ( HIPAA ) guideline study . Hemoglobin ≥ 10 g/dL ≤ 16 g/dL male ≥ 10 g/dL ≤ 14 g/dL female . Transferrin saturation ( TSAT ) ≤ 35 % Serum ferritin ≤ 100 ng/mL . Subjects must body mass index ( BMI ) 19.0 30.0 kg/m2 Subjects must clinically significant abnormal finding physical examination . Subjects currently participate clinical trial another investigational new drug device receive investigational new drug device within 30 day 5 halflives ( whichever longer ) prior randomization study . Subjects parenteral oral iron therapy within 30 day prior dose . Subjects active infection require ongoing treatment . Subjects positive human immunodeficiency virus type 1 type 2 ( HIV1 HIV2 ) antibody , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody test . Abnormal liver function test . Subjects malignancy ( except nonmelanoma skin ) , unless subject receive curative treatment disease free &gt; 2 year . Subjects history risk factor Torsades de pointes ( TdP ) [ e.g. , family history ( parent sibling ) long QT syndrome ] , history fainting , unexplained loss consciousness convulsion . Clinically relevant abnormality screen ECG Subjects sustain supine systolic blood pressure ( SBP ) &gt; 150 mmHg &lt; 90 mmHg diastolic blood pressure ( DBP ) &lt; 45 &gt; 95 mmHg screen baseline . Subjects pulse rate rest &lt; 45 bpm &gt; 100 bpm . Subjects unable stop smoking study ( Day 1 Day 7 ) . Subjects smoke 10 cigarette day . Excessive consumption ( &gt; 6 unit per day ) food beverage xanthine caffeine base ( e.g. , tea , coffee , chocolate , cola ; 1 unit caffeine contain 6 oz coffee , 4 oz energy drink , 24 oz cola , 12 oz tea 3 oz chocolate ) . History regular alcohol consumption exceed 7 drinks/week woman 14 drinks/week men . Subjects allergies iron product , moxifloxacin multiple drug ( two ) allergy report subject determine investigator . Subjects take medication [ exception Tylenol ( acetaminophen ) ≤ 2g/day , multivitamin contain iron , hormonal contraception female hormone replacement therapy ( HRT ) case menopausal subject ] within 7 day 5 halflives ( whichever longer ) prior randomization study . Subjects Investigator determine medical status would preclude patient 's participation protocol , reason , deem Investigator inappropriate study , include subject unable communicate cooperate study . Subjects screen lab result fall outside normal range limit consider clinically significant upon review Investigator . Subjects condition possibly affect drug absorption , [ e.g. , previous surgery gastrointestinal tract ( include removal part stomach , bowel , liver , gall bladder , pancreas ) ] . Subjects evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Exceptions criterion ( e.g. , stable , mild joint disease ) may make follow discussion Medical Monitor . Subjects donate blood blood component within four week prior study . The Investigator instruct subject participate study donate blood blood component four week completion study . Illegal drug user subject history drug abuse within last 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>anemia</keyword>
	<keyword>intravenous iron</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>QTc</keyword>
</DOC>